RANI Cash-Secured Put Strategy
RANI (Rani Therapeutics Holdings, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
RANI (Rani Therapeutics Holdings, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $68.6M, a beta of 0.76 versus the broader market, a 52-week range of 0.387-3.87, average daily share volume of 1.0M, a public-listing history dating back to 2021, approximately 105 full-time employees. These structural characteristics shape how RANI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.76 places RANI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a cash-secured put on RANI?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current RANI snapshot
As of May 15, 2026, spot at $1.10, ATM IV 203.00%, IV rank 42.74%, expected move 58.20%. The cash-secured put on RANI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on RANI specifically: RANI IV at 203.00% is mid-range versus its 1-year history, so the credit collected on a RANI cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 58.20% (roughly $0.64 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RANI expiries trade a higher absolute premium for lower per-day decay. Position sizing on RANI should anchor to the underlying notional of $1.10 per share and to the trader's directional view on RANI stock.
RANI cash-secured put setup
The RANI cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RANI near $1.10, the first option leg uses a $1.05 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RANI chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RANI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $1.05 | N/A |
RANI cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
RANI cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on RANI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on RANI
Cash-secured puts on RANI earn premium while a trader waits to acquire RANI stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning RANI.
RANI thesis for this cash-secured put
The market-implied 1-standard-deviation range for RANI extends from approximately $0.46 on the downside to $1.74 on the upside. A RANI cash-secured put lets a trader earn premium while waiting to acquire RANI at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current RANI IV rank near 42.74% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on RANI should anchor more to the directional view and the expected-move geometry. As a Healthcare name, RANI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RANI-specific events.
RANI cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RANI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RANI alongside the broader basket even when RANI-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on RANI carry tail risk when realized volatility exceeds the implied move; review historical RANI earnings reactions and macro stress periods before sizing. Always rebuild the position from current RANI chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on RANI?
- A cash-secured put on RANI is the cash-secured put strategy applied to RANI (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With RANI stock trading near $1.10, the strikes shown on this page are snapped to the nearest listed RANI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RANI cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the RANI cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 203.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RANI cash-secured put?
- The breakeven for the RANI cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RANI market-implied 1-standard-deviation expected move is approximately 58.20%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on RANI?
- Cash-secured puts on RANI earn premium while a trader waits to acquire RANI stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning RANI.
- How does current RANI implied volatility affect this cash-secured put?
- RANI ATM IV is at 203.00% with IV rank near 42.74%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.